Biogen (BIIB) Total Liabilities (2009 - 2026)
Biogen (BIIB) posted quarterly Total Liabilities of $13.2 billion for Q2 2026, up 23.77% year-over-year from $10.7 billion in Q2 2025, and up 22.22% quarter-over-quarter from $10.8 billion in Q1 2026.
Biogen (BIIB) Total Liabilities (2009 - 2026) Analysis & Trends
Biogen's Total Liabilities history runs 18 years deep, the most recent figure standing at $13.2 billion for Q2 2026.
- In Q2 2026, Total Liabilities rose 23.77% year-over-year to $13.2 billion; the TTM figure through Jun 2026 stood at $13.2 billion (up 23.77% YoY), while the FY2025 annual figure was $11.2 billion, down 1.33% from the prior year.
- Total Liabilities for Q2 2026 stood at $13.2 billion, up from $10.8 billion in the prior quarter.
- The five-year high for Total Liabilities was $13.7 billion in Q3 2023, with the low at $10.7 billion in Q2 2025.
- The 5-year median for Total Liabilities is $11.3 billion (2024), against an average of $11.6 billion.
- The sharpest annual moves came in 2023 and 2026: Total Liabilities slipped 19.08% in 2023, then grew 23.77% in 2026.
- Biogen's Total Liabilities stood at $11.2 billion in 2022, then gained by 7.88% to $12.0 billion in 2023, then declined by 5.91% to $11.3 billion in 2024, then slipped by 1.33% to $11.2 billion in 2025, then climbed by 18.38% to $13.2 billion in 2026.
- Business Quant data shows BIIB's Total Liabilities at $13.2 billion in Q2 2026, $10.8 billion in Q1 2026, and $11.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 13.24 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.24 Bn |
| Mar 31, 2026 | 10.83 Bn |
| Dec 31, 2025 | 11.18 Bn |
| Sep 30, 2025 | 11.00 Bn |
| Jun 30, 2025 | 10.70 Bn |
| Mar 31, 2025 | 11.05 Bn |
| Dec 31, 2024 | 11.33 Bn |
| Sep 30, 2024 | 11.95 Bn |
| Jun 30, 2024 | 10.92 Bn |
| Mar 31, 2024 | 11.35 Bn |
| Dec 31, 2023 | 12.05 Bn |
| Sep 30, 2023 | 13.71 Bn |
| Jun 30, 2023 | 10.70 Bn |
| Mar 31, 2023 | 10.81 Bn |
| Dec 31, 2022 | 11.17 Bn |
| Sep 30, 2022 | 12.09 Bn |
| Jun 30, 2022 | 13.22 Bn |
| Mar 31, 2022 | 12.39 Bn |
| Dec 31, 2021 | 12.92 Bn |
| Sep 30, 2021 | 12.93 Bn |